General Pharmacology of KI-60606

KI-60606의 일반약리작용시험

  • 김은주 (대전광역시 유성구 장동 100 한국화학연구원 부설 안전성평가연구소) ;
  • 김현진 (대전광역시 유성구 장동 100 한국화학연구원 부설 안전성평가연구소) ;
  • 김동연 (경기도 용인시 기흥읍 보라리 359 일양약품주식회사 중앙연구소)
  • Published : 2002.06.01

Abstract

In this study general pharmacological profiles of KI-60606 on the central nervous system, the cardiovascular system and the other organs were investigated. The dosages given were 0,5, 10 and 25 mg/kg and drugs were administered intravenously. The animals used for this study were mice, rats, cats and guinea pigs. KI-60606 showed no effects on general behavior, motor coordination, spontaneous locomotor activity, hexobarbital-induced hypnosis time, body temperature, analgesic activity, anticonvulsant activity and contraction of nictitating membrane in cats. Furthermore KI-60606 showed no effects on blood pressure, heart rate, LVP (left ventricular peak systolic pressure), LVEDP (left ventricular end diastolic pressure), LVDP (left ventricular developing pressure), DP(double product), CFR(coronary flow rate), smooth muscle contraction using guinea pig ileum and gastric secretion at all dosage tested except the increase of gastrointestinal transport and urinary $K^+$ excretion.

Keywords

References

  1. Anderson, W. K., Quagliato, D. A., Hauwilz, R. D., Maray anan, V. L. and Wolpert-DeFilippes, M. K. (1986): 'Synthe-sis, Physical properties and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2 diaminocyclohexane.' Cancer Treat. Rep., 70, 997-1003
  2. Bolli, R. (1991). Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc. Drugs Ther., 5, 249-268 https://doi.org/10.1007/BF00054747
  3. Dunham, W. W. and Miya, T. S. (1957). A note on a simple apparatus of detecting neurological deficit in rats and mice. J. Amer. Pharm. Ass., 10, 208-209
  4. lrwin, S. In., Nodine, J. H. and Siegler, P. E. (1964). Animal and clinical pharmakologic techniques in drug evaluation. Yearbook medical publishers, Chicago, 36-54
  5. Koster, R., Anderson, M. and de Beer, E. J. (1959). Acetic acid for analgesic screening. Fed. Proc., 18, 412-418
  6. Levi, Y., Hershfield, M. S., Femandez-Mejia, C., Polmer, S. H., Scudiery, D., Berger, M. and Sorensen, R. U. (1988). Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr., 113, 312 https://doi.org/10.1016/S0022-3476(88)80271-3
  7. Rang, H. P. (1964). Stimulant actions of volatile anaesthetics on smooth muscle. Br. J. PharmacoI., 27, 256-375
  8. Rogenberg, B., Van Camp, I., Trosko, J. E. and Mansour, V. H. (1969). Platinum compounds: A new class of antitumor agents. Nature, 222, 385-387 https://doi.org/10.1038/222385a0
  9. Shay, H., Komarov S.A., Fels S.S., Merange D., Gruenstein M., and Siplet H. (1945). A simple method for the uniform production of gastric ulceralion in rats. GastroenteroIogy, 5, 43-61
  10. Soloway, M.S., Rose, D. and Weldon, T. (1974). Single and combination chemotherapy for primary murine bladder can-cer. Proc. Am. Assoc. Cancer Res., 15, 7-15
  11. Sung H. J., Lee C. U., Lee M. H., Lee Y. J. (1994). Studies on the Cisplatin Nephrotoxicity ; 2. Effects of cisplatin on the renal proximal tubular glucose transport and alleviating effects of some drugs on die renal toxicity of cisplatin Environmental Mutaens & Carcinogens, 14-1, 13-25
  12. Environmental Mutaens & Carcinogens, 14-1, 13-25Svensson, T. H. and Thieme, G. (1969). An investigation of a new instrument to measure motor activity of small animals. Psychopharmacologia (BerL), 14, 157-163 https://doi.org/10.1007/BF00403689
  13. Swinyard, E. A., Brow, W. C. and Goodman, L. S. (1952). Comparative assays of antiepileptic drugs in mice and rats. J. PharmacoI. ExptI. Therap., 106, 319-330
  14. Watts, J. and Maiorano, L. (1987). Effcct of diltiazem upon globally ischemic rat hearts. Eur. J. PharmacoI., 138, 335-342 https://doi.org/10.1016/0014-2999(87)90471-7
  15. Woodbury, L. A. and Davenport, V. D. (1952). Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch. Int. Pharmacodyn., 92, 97-107